Aurobindo Pharma was founded by Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a group of dedicated professionals on 26th December 1986. Aurobindo started its operations as a private company with a single manufacturing unit of semi-synthetic penicillins (SSPs) in 1988-89.

Aurobindo is into the business of producing and marketing Active Pharmaceutical Ingredients (Bulk actives), Intermediates and Specialty Generic Formulations. It is among the largest manufacturers of Ampicillin and Cloxacillin in India. Its product range includes different therapeutic areas, like cephalosporins, SSPs, CNS, cardio-vascular, gastroenterology, antivirals, etc.
To become a vertically integrated pharmaceutical company, it has made huge investments in APIs and formulations infrastructure. Aurobindo has its headquarters in Hyderabad. To expand its international franchise, Aurobindo has established joint venture/subsidiaries in USA, Brazil and China. In 2005, Aurobindo had received USFDA clearance for its AIDS drug. In the present financial year, Aurobindo is expecting a net sale of about US$ 500 million. With a growth rate of over 71% in the last four years, the company had achieved Rs. 9.78 in 2005-06.

The Board of Directors is composed of the following members:

Mr. P.V.Ramaprasad Reddy, Chairman
Mr. K.Nityananda Reddy, Managing Director
Mr. B.Siva Prasad Reddy, Whole-time Director
Dr. M.Sivakumaran, Whole-time Director
Mr. M. Madan Mohan Reddy, Whole-time Director
Dr. K.A.Balasubramanian, Ph.D., Non-executive Director
Mr. Karam S. Butalia, Non-executive Director
Mr. V.S. Janardhanam, Non-executive Director
Dr. S. Bimal Singh, Non-executive Director
Dr. K. Ramachandran, Non-executive Director
Mr. Srinivas Lanka, Non-executive Director

Products
With the manufacturing and marketing of over 100 Active Pharmaceutical Ingredients (APIs), Aurobindo Pharma is one of the largest Asian API manufacturers. It has API volumes in the following sectors:

  • CNS Range
  • Anti-biotics & Anti-bacterials
  • Cardiovasculars
  • GI Range

The R&D centre of Aurobindo is located on the outskirts of Hyderabad and covers approximately 100,000 sq. feet. It has over 450 scientists and about 500 qualified and well trained chemists, quality assurance and control personnel working dedicatedly.

Its R&D centre is focused on the areas of analytical research, pharmacology, dosage form development, bio-equivalence studies, organic synthesis and drug delivery systems.

Registered & Corporate Office:
Plot # 2, Maitri Vihar, Ameerpet,
Hyderabad – 500 038
Andhra Pradesh, India.
Phone: +91 (40) 6672 5000
Fax: +91(40) 2374 1080 / 2374 6883
Email: info@aurobindo.com

Recent Updates

Aurobindo recieved USFDA approval for Anti-epileptic
US Health regulator USFDA has given the permission for making market generic anti epileptic phenytoin sodium apsules in US. In the statement company state that they finally got the approval from US Food and Drug Administration to manufacture market extended phenytoin sodium capsules USP, 100mg.

Latest News:  Aurobindo Pharma is planning to invest Rs 900 crore in this fiscal year. The plan is to invest mainly  in capital expenditure which includes capacity expansion also.  MD of the company is expecting the investment to be in the range of Rs 800 crore to Rs 900 crore.